Last updated: February 4, 2026
What is the procedural history and current status of the case?
Almirall, LLC filed a lawsuit against Perrigo UK FINCO Limited Partnership in the District of Delaware (1:20-cv-00975). The case concerns patent infringement related to dermatological drug formulations. The complaint was filed on May 8, 2020, alleging violations of patent rights held by Almirall.
Perrigo filed a motion to dismiss on July 24, 2020, specifically challenging the patent infringement claims and jurisdiction. The court denied the motion to dismiss on December 11, 2020, accepting the allegations as sufficient to proceed. A discovery phase followed, including exchange of document requests and depositions, with initial trial scheduled for late 2023.
What patents are at the center of the dispute?
The core dispute involves U.S. Patent No. 10,715,927, covering a topical dermatological composition with specific active ingredients. The patent claims a combination therapy for atopic dermatitis with particular emphasis on the vehicle and active compound ratios.
Almirall alleges Perrigo marketed a generic equivalent infringing on the '927 patent. Perrigo contends that the patent is invalid due to obviousness and lack of novelty, citing prior art references.
What are the main legal challenges?
The primary issues include:
- Infringement: Whether Perrigo’s product infringes on the '927 patent’s claims.
- Patent validity: Whether the patent is invalid for obviousness under 35 U.S.C. § 103, based on prior art references that allegedly disclose similar formulations.
Perrigo’s invalidity contentions hinge on three prior art references published before the patent’s priority date, claiming the invention would have been obvious to a person skilled in the art.
What are the key evidentiary disputes?
The parties dispute the validity of the prior art references. Perrigo challenges the novelty of the patent claims, while Almirall defends the patent’s non-obviousness based on the specific composition and formulation process. Expert testimony regarding the state of the art, expert reports, and prior art references form the crux of the evidentiary debate.
Discovery has uncovered internal communications about formulation development, which Almirall claims demonstrate unexpected benefits, bolstering non-obviousness arguments.
What are the potential implications for the pharmaceutical patent landscape?
This case exemplifies the ongoing litigation around dermatological formulations and the scope of patent rights for combination therapies. A ruling upholding the patent could extend market exclusivity for Almirall’s product, potentially delaying generic entry. Conversely, a finding of invalidity would open the market to Perrigo’s generic, impacting revenues for patent holders.
The case underscores the importance of patent drafting that emphasizes unexpected benefits and detailed formulation specifics to withstand validity challenges.
Key Takeaways
- The case revolves around patent rights for dermatological composition, with infringement and validity at issue.
- The patent in question is U.S. Patent No. 10,715,927.
- Perrigo’s defenses focus on prior art and obviousness, essential for patent validity.
- Discovery and expert testimony are advancing the core factual disputes.
- Outcomes could influence patent strategies in topical dermatology formulations.
FAQs
1. What is the main patent at issue, and what does it cover?
U.S. Patent No. 10,715,927 covers a topical dermatological composition with specific active ingredients and formulation techniques for treating skin conditions like atopic dermatitis.
2. What are Perrigo’s primary defenses?
Perrigo argues the patent is invalid due to obviousness, citing prior art references that allegedly disclose similar formulations before the patent’s priority date.
3. How could this case affect market competition?
A ruling that the patent is valid would prolong Almirall’s market exclusivity, delaying generic competition. An invalidity ruling could enable Perrigo’s product to enter the market, increasing competition.
4. What evidentiary issues are prominent?
The dispute centers on prior art references and the demonstration of unexpected benefits associated with the patent claims, based on internal research and formulation data.
5. When is a decision expected?
Trial is scheduled for late 2023. A ruling on the core issues is likely within several months after trial completion.
References
[1] Court Docket, Almirall, LLC v. Perrigo UK FINCO Limited Partnership, 1:20-cv-00975 (D. Del.)
